Bariatric Surgery Curbs Cancer via Bile Acid Shift: Gastric Bypass Reduces Tumor Growth and Metastasis


2025-07-14 09:18:13 GMT+0800

1. The Surgery-Mechanism Link
Gastric bypass surgery (RYGB) structurally reroutes the digestive tract, creating a small stomach pouch connected directly to the mid-small intestine. While known to lower cancer risk, the mechanism remained elusive until now. The study shows that RYGB diverts bile acids—liver-produced molecules aiding fat digestion—away from their normal path. This exposes bile acids to distinct gut bacteria, chemically converting primary bile acids (cancer-promoting) into secondary forms. Post-surgery, primary bile acids dropped significantly in blood and colon tissue 146.

2. Key Experimental Evidence
Researchers fed mice a high-fat diet until they gained 50% body weight, then performed:

  • RYGB surgery (1/3 of mice)

  • Sham surgery (control, no anatomical changes)

  • Weight-matched groups: Half of RYGB and sham mice lost 20% weight via diet.

After implanting colorectal cancer cells:

  • Tumor size: RYGB mice developed tumors 67% smaller than obese or weight-loss-only mice.

  • Metastasis: Only 1 of 20 RYGB mice had liver metastasis vs. majority in sham groups 157.
    Critically, weight loss alone did not reduce tumors, confirming RYGB’s unique role 69.

3. Bile Acids: The Cancer Switch

  • Primary bile acids (e.g., cholic acid) directly stimulated colorectal cancer growth in lab dishes.

  • Bile diversion surgery—redirecting bile to the lower intestine without stomach alteration—mimicked RYGB’s effects: slashing primary bile acid levels and suppressing tumors as effectively as RYGB 147.
    This proves bile acid redistribution—not weight loss or immune changes—drives the anti-cancer benefit 2.

4. Clinical Implications

  • Drug development: Reducing primary bile acids pharmacologically could replicate RYGB’s effects, offering non-surgical cancer therapy 19.

  • Broader relevance: Bile acid modulation may extend beyond colorectal cancer. Recent Cell studies show microbiota-derived bile acids (e.g., 3-oxo-Δ4,6-LCA) inhibit androgen receptors, enhancing immunotherapy in prostate/bladder cancers 3.

5. Expert Insight

We can develop drugs to lower primary bile acids for cancer patients, mimicking gastric bypass benefits
—Vance Albaugh, Louisiana State University



Please leave a message and We will get back to you in 12hrs.Thanks!